| Thane Wettig |
Thane Wettig is currently the Chief Executive Officer & Director at FibroGen, Inc. He previously worked as the Chief Commercial Officer at Intarcia Therapeutics, Inc. and as the Vice President-Diabetes Brands Global Marketing at Lilly Diabetes from 2004 to 2009. Mr. Wettig completed his undergraduate degree and MBA at Washington University in St. Louis. |
| Deyaa Adib |
Deyaa Adib is currently the Chief Medical Officer & Senior Vice President at FibroGen, Inc. Prior to this, he held positions at Baxalta, Inc. as the Global Therapeutics Head-Solid Tumors, ARIAD Pharmaceuticals, Inc. as the Head-Hematologic Malignancies, Triumvira Immunologics, Inc. as the Chief Medical Officer, and Blueprint Medicines Corp. as the Vice President-Late Stage Development. Dr. Adib completed his undergraduate degree at KasrAlAiny School of Medicine. |
| Leanne C. Price |
Leanne C. Price currently works at FibroGen, Inc., as Chief Intellectual Property Officer from 1999 and The State Bar of California, as Member. Ms. Price also formerly worked at Incyte Pharmaceuticals, Inc., as Senior Attorney-Patent and Skjerven, Morrill, MacPherson, Franklin & Friel LLP, as Associate. Ms. Price received her graduate degree from Berkeley Law University of California and undergraduate degree from Revelle College. |
| Michael D. Lowenstein |
Michael D. Lowenstein is currently the Chief Legal Officer at FibroGen, Inc. He is also a Member of The State Bar of California and a Member-Supervisory Board at FibroGen (China) Medical Technology Development Co. Ltd. Lowenstein received his undergraduate degree from Brown University in 1995 and his graduate degree from The Trustees of Columbia University in The City of New York in 1999. |
| Elias Kouchakji |
Elias Kouchakji's career history includes current and former positions in the pharmaceutical industry. Currently, he is the Senior VP-Clinical Development & Drug Safety at FibroGen, Inc. Previously, he held positions such as Executive Director-Medical & Safety at Amgen, Inc., Director-Drug Safety & Pharmacovigilance at EMD Serono, Inc., Global Head-Pharmacovigilance & Risk Management at Elan Pharmaceuticals LLC, Head-US Safety at Hoffmann-La Roche, Inc., and Global Head-Pharmacovigilance & Risk Management at Perrigo Co. Plc. Dr. Kouchakji obtained his doctorate degree from Damascus University. |
| John Hunter |
John Hunter is currently the Chief Scientific Officer at FibroGen, Inc. He previously worked as a Senior Director at XOMA Corp., Chief Scientific Officer at Compugen Ltd., Vice President-Antibody R&D at Compugen, Inc. (United States), and Chief Executive & Scientific Officer at Keyhole Therapeutics, Inc. Dr. Hunter received his undergraduate degree from Hartwick College and his doctorate from The University of California, San Francisco. |
| Juan Graham |
Juan Graham is currently the Chief Financial Officer & Senior Vice President at FibroGen, Inc. Prior to this, he worked as the Global CFO & VP-Finance Supply Chain at Johnson & Johnson, Inc. from 2016 to 2019. Mr. Graham holds an MBA from McGill University and an undergraduate degree from Instituto Tecnológico y de Estudios Superiores de Monterrey. |
| Tricia Stewart |
Tricia Stewart is currently the Chief People Officer at FibroGen, Inc. Her former job was as Vice President-Human Resources at Pharma International, Inc. She obtained an undergraduate degree from Fairfield University. |
| Rahul Rajan Kaushik |
Rahul Rajan Kaushik is currently working as SVP-Technical Operations & Manufacturing at FibroGen, Inc. Previously, he worked as Head-External Manufacturing at Nektar Therapeutics. Dr. Kaushik holds a doctorate degree from Stanford University and undergraduate and graduate degrees from the Indian Institute of Technology Bombay. |
| James A. Schoeneck |
James A. Schoeneck is currently the Chairman at FibroGen, Inc. since 2020. He is also the Director at Calidi Biotherapeutics, Inc. (United States) since 2020 and an Independent Director at Calidi Biotherapeutics, Inc. Additionally, Mr. Schoeneck has held several former positions including President, Chief Executive Officer & Director at Assertio Therapeutics, Inc. from 2011 to 2017, Chief Executive Officer at BrainCells, Inc. from 2005 to 2011, Chief Executive Officer at ActivX Biosciences, Inc. in 2003 and Director at AnaptysBio, Inc. from 2015 to 2018. He also served as Vice President & General Manager-Immunology at Centocor, Inc. from 1996 to 1999 and as President, Chief Executive & Operating Officer at Prometheus Laboratories, Inc. from 1999 to 2003. Mr. Schoeneck's education includes an undergraduate degree from Jacksonville State University in 1979. |
| Kirk A. Christoffersen |
Kirk A. Christoffersen is currently the Chief Business Officer at FibroGen, Inc. He previously worked as the Vice President of Corporate Development at GlobeImmune, Inc. and as the Senior VP of Corporate & Business Development at Compugen Ltd. He also held positions at Gilead Sciences, Inc. and OSI Pharmaceuticals, Inc. Additionally, he worked as the Chief Business Officer at Arch Oncology, Inc. and as a Principal at Sirna Therapeutics, Inc. Christoffersen received his undergraduate degree from the University of Michigan and his MBA from Daniels College of Business. |
| Jeffrey William Henderson |
Jeffrey William Henderson is currently the Chairman at Halozyme Therapeutics, Inc., an Independent Director at Becton, Dickinson & Co., an Independent Director at QUALCOMM, Inc., an Independent Director at FibroGen, Inc., a Director at Affordable Care LLC, a Director at Britannia Refined Metals Ltd., a Director at ACI Group Holdings, Inc., a Trustee at Columbus School for Girls, and the President of Jwh Consulting LLC. In the past, Mr. Henderson worked as an Advisory Director at Berkshire Partners LLC from 2015 to 2019, a Director at Integrated DNA Technologies, Inc., the Chief Financial Officer at Cardinal Health, Inc. from 2010 to 2014, the Treasurer-Asia Pacific Regional Treasury Center at General Motors Corp. from 1988 to 1998, the Treasurer, Vice President & Controller at Eli Lilly & Co. from 1998 to 2005, the President & General Manager at Eli Lilly Canada, Inc. from 1998 to 2005, and the Chief Financial Officer at IBC Vehicles Ltd. from 1988 to 1998. Mr. Henderson obtained an undergraduate degree from Kettering University and an MBA from Harvard Business School. |
| Jeffrey L. Edwards |
Jeffrey L. Edwards is currently an Independent Director at Bio-Rad Laboratories, Inc., Lifecore Biomedical, Inc., MAP Pharmaceuticals LLC, Viamet Pharmaceuticals, Inc., BioTheryX, Inc., Viamet Pharmaceuticals Corp., FibroGen, Inc., and Clearside Biomedical, Inc. He previously worked as the Chief Financial Officer & Executive VP-Finance at Allergan, Inc. from 2014 to 2015. Before that, he was a Principal at Banque Paribas Belgique SA from 1992 to 1993 and at Security Pacific National Bank from 1983 to 1992. He obtained his undergraduate degree from Muhlenberg College. |
| May Kin Ho |
May Kin Ho is currently serving as a Director at PAREXEL International Corp., BioMarin Pharmaceutical, Inc., Agios Pharmaceuticals, Inc., FibroGen, Inc., The Aaron Diamond AIDS Research Center, Parexel International Corp. Ltd., Institute For Protein Innovation, Inc., Neumora Therapeutics, Inc., and as a Venture Partner at Qiming Venture Partners Ltd. Dr. Ho is also the Managing Partner at Viridian Global Logistics, Inc. In the past, Dr. Ho held positions as an Independent Director at PAREXEL International Corp., GRAIL LLC, and as a Director-Strategic Planning, Marketing & Research at DuPont Merck Pharmaceutical Co. and Dupont De Nemours & Co., Inc. Dr. Ho also worked at The Goldman Sachs Group, Inc. as a Partner & Co-Head-Healthcare and at Goldman Sachs & Co. LLC as a Research Analyst. Dr. Ho obtained a doctorate degree from the State University of New York at Downstate Medical Center in 1980 and an undergraduate degree from the same institution in 1975. |
| Benjamin F. Cravatt |
Benjamin F. Cravatt is the founder of ActivX Biosciences, Inc. (founded in 2000), Abide Therapeutics, Inc. (founded in 2011), Vividion Therapeutics, Inc. (founded in 2014), Belharra Therapeutics, Inc. (founded in 2021), and Boundless Bio, Inc. (founded in 2018). Dr. Cravatt is also the founder of Kisbee Therapeutics, Inc., Kojin Therapeutics, Inc., Magnet Biomedicine, Inc... Dr. Cravatt's current job(s) include being an Independent Director at FibroGen, Inc. since 2020, a Director at Inception Sciences, Inc., a Director at Sea Pharmaceuticals LLC since 2019, a Director at Autobahn Therapeutics, Inc. since 2020, and a Member of the National Academy of Sciences, American Academy of Arts & Sciences, National Academy of Medicine (United States), and National Academy of Inventors. Dr. Cravatt's former job(s) include being a Professor at The Scripps Research Institute and an Advisor at 5AM Venture Management LLC in 2010. Dr. Cravatt's education history includes an undergraduate degree from Stanford University and a doctorate from The Scripps Research Institute in 1996. |
| Kalevi Kurkijärvi |
Kalevi Kurkijärvi is a businessperson who has been at the head of 14 different companies and is Chairman & Founding Partner at Innomedica Oy, Chairman of Innomedica Ltd., Chairman & Chief Executive Officer for Biketex Ltd., Chairman at Idea Development ID Oy, President & Chief Executive Officer for Pharmacia Diagnostics Production Oy and Managing Director at FibroGen Europe Oy. He is also on the board of FibroGen, Inc. and Executive Vice President at Wallac Oy.
In the past Kalevi Kurkijärvi occupied the position of Chairman at Hytest Oy, Chairman of Bio Orbit Oy, Chairman of Biotie Therapies Oy, Chairman & Chief Executive Officer at Bio Fund Management Oy, Chairman for MAP Medical Technologies Oy, Chairman at Stick Tech Oy, Chairman for Hormos Medical Oy and President & Chief Executive Officer at Phadia AB.
Dr. Kurkijärvi received a doctorate from the University of Turku. |
| Gerald Lema |
Gerald Lema is currently an Independent Director at FibroGen, Inc., a Director at Catalyst, Inc., a Representative Director & Partner at Cylon Capital KK, and a Partner at Reaction Capital. Previously, he served as Chairman & President-Asia Pacific & Japan at Baxter International, Inc. from 2007 to 2015, as well as Chairman at Abbott Japan LLC and Vice President-Asia Pacific Division at Abbott Laboratories. Lema received an undergraduate degree from Universidad del Valle and an MBA from A.B. Freeman School of Business. |
| Aoife M. Brennan |
Aoife M. Brennan is currently the President, Chief Executive Officer & Director at Synlogic Operating Co., Inc. She is also a Director at FibroGen, Inc., Cerevance, Inc., and an Advisor at Atlas Venture Advisors, Inc. Previously, she held the positions of President, Chief Executive Officer & Director at Synlogic, Inc. from 2016 to 2024, Director-Clinical Development at Tolerx, Inc. from 2008 to 2011, Independent Director at Ra Pharmaceuticals, Inc. from 2018 to 2020, and Vice President & Head-Rare Disease Innovation Unit at Biogen, Inc. from 2011 to 2016. Dr. Brennan holds a doctorate degree from Trinity College Dublin and a graduate degree from Harvard Medical School (conferred in 2008). |
| Suzanne Blaug |
Suzanne Blaug is an Independent Director at FibroGen, Inc. She previously worked as Managing Director at Johnson & Johnson, SVP-Global Marketing & Commercial Development at Amgen, Inc., Head at Janssen Alzheimer Immunotherapy, Principal at EMEA Capital LLP, and Vice President-Europe Strategic Marketing at Janssen Global Services LLC. Blaug holds an undergraduate degree from The University of North Carolina at Chapel Hill and an MBA from Kellogg School of Management. |
